MedTrace Logo

Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease

NCT00180544 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2008-07-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of the RX HERCULINK 14 Peripheral Stent System in treating atherosclerotic renal artery stenosis.

Conditions

  • Renal Artery Obstruction

Interventions

DEVICE

Stenting: Renal Artery

Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Stephen Ramee, M.D. · Alton Ochsner Medical Foundation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-07-31
Primary Completion
2004-08-31
Completion
2004-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00180544 on ClinicalTrials.gov